CiteFacts · FDA Drug Shortages · FDA source
Hydrocortisone Sodium Succinate Injection
Status
FDA source rows are resolved or no longer current.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Cipla Limited | Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06) | Not stated | 02/24/2026 |
| Hospira, Inc., a Pfizer Company | Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12) | Not stated | 02/24/2026 |
Source facts
Grouped generic ingredient: Hydrocortisone Sodium Succinate Injection · 8 package records · Latest FDA row update: 02/24/2026
Therapeutic categories: Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Pulmonary/Allergy, Renal, Rheumatology
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.